admin,  —

“Watch the video shared by the Canadian Pulmonary Fibrosis Foundation to understand what is like to live with IPF through the eyes of patients and their families.” Learn more about Esbriet that addresses Idiopathic Pulmonary Fibrosis: http://bit.ly/Esbriet…

Promedior recently announced the initiation of a Phase 2 trial of PRM-151, an experimental anti-fibrotic agent, in patients with Idiopathic Pulmonary Fibrosis (IPF). Previous clinical Phase 1 studies also conducted by Promedior, a biotechnology company working on therapeutics for the treatment of fibrosis, led to this placebo-controlled Phase 2 study, which…

Mutations in telomere genes may cause pulmonary fibrosis, emphysema and impact life expectancy, according to new research results. Telomeres are found at the end of chromosomes, where they act like a protective tip. When cells divide, telomeres shorten. Over the lifespan, with multiple cell division and aging, telomeres get shorter. Eventually telomeres become so short…

A leader in plant-based biotechnology, iBio, Inc. announced a key new U.S. patent, called “Yersinia pestis Antigens, Vaccine Compositions and Related Methods.” It includes plague antigens that work with the Company’s iBioModulator™ thermostable immunomodulator protein. The technology is directed at providing protection against pneumonic plague, which could be used as a potential form…

Pulmonary fibrosis may run in the family, based on the frequent occurrence of this disorder in people who are related, according to an article titled Familial Pulmonary Fibrosis recently published in Revue des Maladies Respiratoires by a group from the Centre de Compétence Maladies Rares Pulmonaires, Hôpital…

Researchers in Ann Arbor Michigan and at Cornell University in New York have found that specific types of white blood cells (leukocytes) might be used to predict the disease progression of idiopathic pulmonary fibrosis (IPF). The study appeared in the December 22 issue of…

A new study provides improved understanding of the challenges faced by people with Idiopathic Pulmonary Fibrosis (IPF) and their caregivers, which could help in the development of supportive care and could also improve quality of life in people afflicted with IPF. The study appeared December 23rd, 2014, in the…

Scientists from Japan have found that blood levels of the surfactant protein SP-D could be a good biomarker for idiopathic pulmonary fibrosis, since it leaks into the blood more easily than another similar surfactant protein, called SP-A. The study appeared in the journal BioMedCentral Pulmonary Medicine on December…

Scientists in Iran have found that the lipid-lowering agent atorvastatin may reduce pulmonary injury and fibrosis caused by paraquat–a poison that is toxic to the nervous system. The article was published in the December issue of Advanced Pharmaceutical Bulletin. Pulmonary fibrosis is characterized by thick, scarred lung tissue,…

Boehringer Ingelheim recently announced European Union (EU) approval of nintedanib (brand name OFEV®) for idiopathic pulmonary fibrosis (IPF) treatment. The committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion, which means that the treatment can now be marketed, sold, and used…